Finvest
BTSG Healthcare Services · Home health · Specialty pharmacy · Post-acute care · Thesis updated June 14, 2026

Pharmacy growth now carries the story

01 Running thesis

A cleaner company, a higher bar

BrightSpring has moved from a balance sheet repair story to an execution story. The Community Living sale closed on March 30, 2026, and company leverage was 2.27x at March 31, 2026. That gives management more room to invest, pay for small acquisitions, and focus on the core businesses.

The bull case is now simple: Pharmacy Solutions keeps growing fast, Provider Services gets better as new assets are folded in, and the company reaches its raised 2026 adjusted EBITDA target of $795 million to $825 million. Specialty and Infusion scripts grew about 30% year over year in Q1 2026, which is the clearest sign that demand is still strong.

The bear case has also changed. Debt is less of the main worry. The key question is whether Specialty Pharmacy growth can stay high enough to justify the stock's price. A second question is whether the Amedisys and LHC branches can be integrated without slowing margins or distracting management.

This is a stronger story than it was before Q1 2026, but it is not a cheap-looking one. Investors should watch whether the company keeps beating guidance, not just whether revenue rises.

May 2026▲Q1 2026 beat expectations, and management raised full-year adjusted EBITDA guidance to $795 million to $825 million. Leverage fell to 2.27x after the Community Living sale closed.
Feb 2026▲The 2025 update gave a clearer path for the Community Living sale and balance sheet repair. It also framed the Amedisys and LHC branch deal as a new Provider Services growth test.
Oct 2025→Q3 2025 showed continued fast Pharmacy Solutions growth, but no major change to the pending divestiture or acquisition questions. The thesis stayed positive but still depended on closing and integration.
Aug 2025▲BrightSpring announced a definitive agreement to buy home health and hospice assets from Amedisys and related centers from UnitedHealth Group. That added a clear Provider Services expansion catalyst.
May 2025→Q1 2025 showed strong continuing operations, with Pharmacy Solutions revenue up 28.1% and Provider Services revenue up 12.1%. The FTC second request on the Community Living sale added timing risk.
02 Business model

Care at home, paid by insurers

BrightSpring makes money by serving high-need patients in lower-cost settings, often at home. It gets paid by government programs and private insurers for pharmacy, home health, hospice, rehab, and related care services.

The company tries to stand out by linking pharmacy and care services inside one operating system. The idea is that better medication support and care coordination can reduce hospital visits and make BrightSpring harder to replace.

The model depends on scale. More patients, more pharmacy volume, and more local branches can spread fixed costs across a larger base. That is why small tuck-in acquisitions can matter, especially when they add new local markets.

The weak point is reimbursement. If payers lower what they pay for specialty drugs, home health, or hospice, BrightSpring may need more volume just to hold profit steady.

03 Product portfolio

What BrightSpring sells

Growth engine

Specialty Pharmacy

This is the largest growth driver inside Pharmacy Solutions. It serves patients using complex, often expensive medicines, including oncology-related therapies.

Growth engine

Infusion Pharmacy

Infusion services help patients receive drugs outside the hospital. Management said Specialty and Infusion scripts grew about 30% year over year in Q1 2026.

Steady

Home and Community Pharmacy

This business supports patients who need ongoing medication management. It adds recurring revenue and helps link pharmacy data with care delivery.

Steady

Home Health and Hospice

These services sit in Provider Services. The Amedisys and LHC branch acquisition expanded this part of the company.

Steady

Rehabilitation Services

Rehab services help patients recover after illness, injury, or surgery. This fits BrightSpring's focus on care outside high-cost hospital settings.

Option

Care Coordination

Care coordination connects pharmacy and provider services. If it reduces hospitalizations, it can help BrightSpring win more payer and patient relationships.

04 Business segments

The mix is mostly pharmacy

Pharmacy Solutions88%growing fast
Provider Services12%growing fast

Segment mix is from the three months ended March 31, 2026. Pharmacy Solutions was 87.8% of revenue, so changes in specialty drug volume can move the whole company.

05 Risk factors

What could break the thesis

Specialty script growth slows

High impact · Medium odds

The bull case depends on Specialty and Infusion scripts staying strong. Q1 2026 growth was about 30% year over year, and Infusion and Specialty Pharmacy revenue rose 35.5%. If growth falls sharply, investors may question the company's premium growth story.

We watchQuarterly Specialty and Infusion script growth, plus Infusion and Specialty Pharmacy revenue growth.

Amedisys and LHC integration misses

Medium impact · Medium odds

Provider Services grew 27.9% year over year in Q1 2026, helped by the acquired Amedisys and LHC branches. Management expects about $30 million of 2026 EBITDA contribution from those assets. The risk is that branch integration takes longer, costs more, or fails to lift margins toward the legacy Provider Services level.

We watchProvider Services margin, branch retention, and progress toward the roughly $30 million EBITDA contribution target.

Reimbursement pressure rises

High impact · Medium odds

BrightSpring is paid by government programs and private insurers. Changes tied to pharmacy reimbursement, including pressure linked to the Inflation Reduction Act, could reduce profit per prescription. Management has said the impact is manageable, but this remains a core risk.

We watchGross margin in Pharmacy Solutions and management comments on IRA-related reimbursement.

Acquisition discipline slips

Medium impact · Low odds

With leverage down to 2.27x, management has more room to pursue tuck-in acquisitions. That can help growth if deals are small, local, and well priced. It can hurt shareholders if the company overpays or buys assets that are hard to integrate.

We watchDeal size, purchase price, leverage after deals, and whether new assets add EBITDA on schedule.

Margin mix stays under pressure

Medium impact · Medium odds

Pharmacy Solutions is growing faster than the rest of the company and made up 87.8% of Q1 2026 revenue. Earlier filings showed pharmacy gross margin pressure from mix shift toward Infusion and Specialty Pharmacy. Fast revenue growth is helpful, but investors need to see that profit grows too.

We watchAdjusted EBITDA margin, Pharmacy Solutions gross margin, and second-half 2026 efficiency updates.
06 Quick answers

In one breath

What does BrightSpring Health Services do?

BrightSpring provides healthcare services for complex patients, often in the home. Its main businesses are specialty pharmacy, infusion pharmacy, home health, hospice, rehab, and care coordination.

Why is Pharmacy Solutions so important for BTSG?

Pharmacy Solutions was 87.8% of Q1 2026 revenue. Its Infusion and Specialty Pharmacy revenue rose 35.5% year over year, making it the main growth engine.

Did the Community Living divestiture happen?

Yes. BrightSpring completed the Community Living divestiture on March 30, 2026. After that, company leverage was 2.27x at March 31, 2026.

What should investors watch next?

The biggest items are 2026 adjusted EBITDA guidance of $795 million to $825 million, Specialty and Infusion script growth, and integration of the Amedisys and LHC assets. If those miss, the thesis weakens.